Omnicell Inc. (NASDAQ:OMCL) saw unusually-strong trading volume on Friday . Approximately 160,274 shares changed hands during mid-day trading, a decline of 7% from the previous session’s volume of 172,802 shares.The stock last traded at $35.95 and had previously closed at $35.96.

OMCL has been the subject of several recent research reports. FBR & Co reiterated a “buy” rating and issued a $35.00 price target on shares of Omnicell in a research report on Monday, May 2nd. Topeka Capital Markets reduced their price target on Omnicell from $38.00 to $37.00 and set a “buy” rating for the company in a research report on Monday, March 21st. Finally, Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Omnicell currently has an average rating of “Buy” and an average target price of $37.25.

The firm has a market capitalization of $1.29 billion and a price-to-earnings ratio of 53.95. The company has a 50-day moving average of $33.89 and a 200-day moving average of $29.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, April 28th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.09. The firm had revenue of $171 million for the quarter, compared to the consensus estimate of $167.18 million. Omnicell’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.29 earnings per share. On average, equities analysts predict that Omnicell Inc. will post $1.56 EPS for the current year.

In other news, EVP Robin Gene Seim sold 5,302 shares of the stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $34.75, for a total transaction of $184,244.50. Following the transaction, the executive vice president now directly owns 55,420 shares of the company’s stock, valued at approximately $1,925,845. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jorge R. Taborga sold 1,933 shares of the stock in a transaction on Friday, May 20th. The shares were sold at an average price of $30.73, for a total value of $59,401.09. Following the transaction, the vice president now directly owns 52,667 shares in the company, valued at $1,618,456.91. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in OMCL. Edge Asset Management Inc. boosted its position in shares of Omnicell by 41.0% in the fourth quarter. Edge Asset Management Inc. now owns 378,276 shares of the company’s stock worth $11,757,000 after buying an additional 110,035 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its position in shares of Omnicell by 32.4% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 412,600 shares of the company’s stock worth $12,824,000 after buying an additional 100,900 shares in the last quarter. Comerica Bank boosted its position in shares of Omnicell by 8.9% in the fourth quarter. Comerica Bank now owns 68,602 shares of the company’s stock worth $1,885,000 after buying an additional 5,629 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in shares of Omnicell by 32.0% in the fourth quarter. Mutual of America Capital Management LLC now owns 152,422 shares of the company’s stock worth $4,737,000 after buying an additional 36,911 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Omnicell by 3.0% in the fourth quarter. Principal Financial Group Inc. now owns 241,880 shares of the company’s stock worth $7,518,000 after buying an additional 6,979 shares in the last quarter.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.